{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:24:46Z","timestamp":1787117086065,"version":"build-2736575974"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple primary malignant neoplasms (MPMNs) refers to the concurrent or sequential development of at least two distinct primary malignant tumors within the body, arising from the same organ or different organs. The current manuscript discusses the unique clinical case of a female patient diagnosed with concomitant metastatic ALK-positive NSCLC and del 5q-MDS and was treated for both entities with oral systemic treatments only with a remarkable response for both diseases.<\/jats:p>","DOI":"10.3389\/fonc.2026.1909434","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:35:28Z","timestamp":1787114128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ALK-fusion-positive non-small cell lung cancer concomitant with 5q deletion myelodysplastic syndrome: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Mohammad Hassan","family":"Hodroj","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cedars Cancer Centre, McGill University Health Center","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Moukadem","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12885-025-15509-7","article-title":"Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment","volume":"26","author":"Shao","year":"2026","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.3390\/cancers14225531","article-title":"Myelodysplastic syndromes with isolated del(5q): Value of molecular alterations for diagnostic and prognostic assessment","volume":"14","author":"Acha","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3892\/ol.2025.15351","article-title":"Multiple primary Malignant neoplasms and long-term survival: A case report","volume":"30","author":"Xie","year":"2025","journal-title":"Oncol Lett"},{"key":"B6","doi-asserted-by":"publisher","first-page":"740A","DOI":"10.1016\/j.chest.2016.08.835","article-title":"The rare co-existence of primary small cell lung cancer and myelodysplastic syndrome: A treatment challenge","volume":"150","author":"Victoria","year":"2016","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12920-021-01147-y","article-title":"Secondary myelodysplastic syndromes identified via next-generation sequencing in a non-small cell lung cancer patient","volume":"14","author":"Feng","year":"2021","journal-title":"BMC Med Genomics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00581","article-title":"Lorlatinib versus Crizotinib in patients with advanced ALK-positive non\u2013small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909434\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:35:39Z","timestamp":1787114139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1909434\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":9,"alternative-id":["10.3389\/fonc.2026.1909434"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1909434","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1909434"}}